Editas Historical Income Statement

EDIT Stock

USD 1.22 0.02 1.61%

Historical analysis of Editas Medicine income statement accounts such as Selling General Administrative of 57.9 M or Total Revenue of 94.3 M can show how well Editas Medicine performed in making a profits. Evaluating Editas Medicine income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Editas Medicine's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Editas Medicine latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Editas Medicine is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

About Editas Income Statement Analysis

Editas Medicine Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Editas Medicine shareholders. The income statement also shows Editas investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Editas Medicine Income Statement Chart

At this time, Editas Medicine's Depreciation And Amortization is comparatively stable compared to the past year. Total Revenue is likely to gain to about 94.3 M in 2025, despite the fact that Gross Profit is likely to grow to (85.1 M).

Selling General Administrative Other Operating Expenses Ebit Research Development Cost Of Revenue Net Income Applicable To Common Shares

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Editas Medicine. It is also known as Editas Medicine overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Editas Medicine income statement and represents the costs associated with goods and services Editas Medicine provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Editas Medicine's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.At this time, Editas Medicine's Depreciation And Amortization is comparatively stable compared to the past year. Total Revenue is likely to gain to about 94.3 M in 2025, despite the fact that Gross Profit is likely to grow to (85.1 M).

	2022	2023	2024	2025 (projected)
Total Operating Expenses	245.7M	247.3M	284.4M	168.4M
Cost Of Revenue	6.3M	177.7M	204.3M	214.5M

Total Operating Expenses Cost Of Revenue

Editas Medicine income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Income	Net Interest Income	Non Operating Income Net Other	Reconciled Depreciation
Depreciation And Amortization		0.57	0.8	0.81	-0.26	0.87	-0.84	-0.88	-0.83	0.88	-0.82	0.66	0.87	-0.8	0.6	-0.82	0.28	0.76	0.75	0.45	0.9
Interest Expense	0.57		0.85	0.53	-0.35	0.81	-0.82	-0.79	-0.8	0.79	-0.81	0.45	0.81	-0.79	0.48	-0.78	0.04	0.61	0.62	0.49	0.64
Selling General Administrative	0.8	0.85		0.71	-0.17	0.98	-0.96	-0.94	-0.95	0.95	-0.95	0.63	0.98	-0.93	0.57	-0.94	0.11	0.63	0.62	0.59	0.75
Total Revenue	0.81	0.53	0.71		-0.33	0.77	-0.62	-0.66	-0.6	0.78	-0.6	0.93	0.77	-0.54	0.73	-0.56	0.38	0.84	0.83	0.75	0.7
Gross Profit	-0.26	-0.35	-0.17	-0.33		-0.2	0.16	0.28	0.15	-0.21	0.15	-0.5	-0.2	0.13	-0.3	0.15	-0.37	-0.76	-0.76	0.11	-0.38
Other Operating Expenses	0.87	0.81	0.98	0.77	-0.2		-0.94	-0.93	-0.93	1.0	-0.93	0.65	1.0	-0.91	0.62	-0.91	0.15	0.68	0.67	0.64	0.85
Operating Income	-0.84	-0.82	-0.96	-0.62	0.16	-0.94		0.98	0.99	-0.92	0.99	-0.5	-0.94	0.99	-0.52	0.99	-0.05	-0.59	-0.58	-0.5	-0.77
Net Income From Continuing Ops	-0.88	-0.79	-0.94	-0.66	0.28	-0.93	0.98		0.99	-0.92	0.99	-0.56	-0.93	0.98	-0.46	0.99	-0.03	-0.68	-0.67	-0.44	-0.81
Ebit	-0.83	-0.8	-0.95	-0.6	0.15	-0.93	0.99	0.99		-0.91	1.0	-0.49	-0.93	1.0	-0.43	1.0	0.05	-0.58	-0.57	-0.49	-0.76
Research Development	0.88	0.79	0.95	0.78	-0.21	1.0	-0.92	-0.92	-0.91		-0.91	0.66	1.0	-0.88	0.63	-0.89	0.16	0.69	0.69	0.65	0.88
Ebitda	-0.82	-0.81	-0.95	-0.6	0.15	-0.93	0.99	0.99	1.0	-0.91		-0.48	-0.93	1.0	-0.42	1.0	0.06	-0.57	-0.56	-0.48	-0.75
Cost Of Revenue	0.66	0.45	0.63	0.93	-0.5	0.65	-0.5	-0.56	-0.49	0.66	-0.48		0.65	-0.42	0.69	-0.45	0.45	0.86	0.85	0.63	0.53
Total Operating Expenses	0.87	0.81	0.98	0.77	-0.2	1.0	-0.94	-0.93	-0.93	1.0	-0.93	0.65		-0.91	0.62	-0.91	0.15	0.68	0.67	0.64	0.85
Income Before Tax	-0.8	-0.79	-0.93	-0.54	0.13	-0.91	0.99	0.98	1.0	-0.88	1.0	-0.42	-0.91		-0.38	1.0	0.09	-0.53	-0.52	-0.43	-0.74
Total Other Income Expense Net	0.6	0.48	0.57	0.73	-0.3	0.62	-0.52	-0.46	-0.43	0.63	-0.42	0.69	0.62	-0.38		-0.39	0.77	0.64	0.64	0.6	0.55
Net Income	-0.82	-0.78	-0.94	-0.56	0.15	-0.91	0.99	0.99	1.0	-0.89	1.0	-0.45	-0.91	1.0	-0.39		0.06	-0.56	-0.54	-0.42	-0.74
Income Tax Expense	0.28	0.04	0.11	0.38	-0.37	0.15	-0.05	-0.03	0.05	0.16	0.06	0.45	0.15	0.09	0.77	0.06		0.42	0.41	0.05	0.21
Interest Income	0.76	0.61	0.63	0.84	-0.76	0.68	-0.59	-0.68	-0.58	0.69	-0.57	0.86	0.68	-0.53	0.64	-0.56	0.42		1.0	0.41	0.75
Net Interest Income	0.75	0.62	0.62	0.83	-0.76	0.67	-0.58	-0.67	-0.57	0.69	-0.56	0.85	0.67	-0.52	0.64	-0.54	0.41	1.0		0.42	0.75
Non Operating Income Net Other	0.45	0.49	0.59	0.75	0.11	0.64	-0.5	-0.44	-0.49	0.65	-0.48	0.63	0.64	-0.43	0.6	-0.42	0.05	0.41	0.42		0.41
Reconciled Depreciation	0.9	0.64	0.75	0.7	-0.38	0.85	-0.77	-0.81	-0.76	0.88	-0.75	0.53	0.85	-0.74	0.55	-0.74	0.21	0.75	0.75	0.41

Click cells to compare fundamentals

Editas Medicine Account Relationship Matchups

Editas Medicine income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	4.0M	5.1M	6.3M	6.1M	7.0M	7.3M
Interest Expense	7.3M	2.6M	5.7M	4.2M	4.9M	3.0M
Selling General Administrative	67.6M	76.2M	70.7M	69.7M	80.1M	57.9M
Total Revenue	90.7M	25.5M	19.7M	78.1M	89.8M	94.3M
Gross Profit	90.7M	25.5M	19.7M	(99.5M)	(89.6M)	(85.1M)
Other Operating Expenses	225.6M	218.7M	245.7M	247.3M	284.4M	168.4M
Operating Income	(134.8M)	(193.1M)	(226.0M)	(169.2M)	(152.3M)	(159.9M)
Net Income From Continuing Ops	(116.0M)	(192.5M)	(220.4M)	(195.1M)	(175.6M)	(184.4M)
Ebit	(134.8M)	(193.1M)	(226.0M)	(169.2M)	(152.3M)	(159.9M)
Research Development	158.0M	142.5M	175.0M	177.7M	204.3M	110.5M
Ebitda	(130.9M)	(188.1M)	(219.6M)	(163.1M)	(146.8M)	(154.1M)
Cost Of Revenue	158.0M	5.1M	6.3M	177.7M	204.3M	214.5M
Total Operating Expenses	225.6M	218.7M	245.7M	247.3M	284.4M	168.4M
Income Before Tax	(116.0M)	(192.5M)	(220.4M)	(153.2M)	(137.9M)	(144.8M)
Total Other Income Expense Net	18.9M	644K	5.5M	16.0M	18.4M	19.3M
Net Income Applicable To Common Shares	(133.7M)	(116.0M)	(192.5M)	(220.4M)	(198.4M)	(188.5M)
Net Income	(109.4M)	(185.1M)	(204.4M)	(153.2M)	(137.9M)	(144.8M)
Income Tax Expense	(6.6M)	(7.4M)	(16.1M)	5.9M	6.8M	7.1M
Interest Income	2.6M	2.3M	4.2M	13.9M	16.0M	16.8M
Net Interest Income	2.6M	2.3M	4.2M	13.9M	16.0M	16.8M
Non Operating Income Net Other	7.2M	18.9M	644K	5.5M	6.3M	5.6M
Reconciled Depreciation	4.0M	5.1M	6.3M	6.2M	7.1M	4.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Editas Historical Income Statement

About Editas Income Statement Analysis

Editas Medicine Income Statement Chart

Other Operating Expenses

Cost Of Revenue

Net Income Applicable To Common Shares

Editas Medicine income statement Correlations

Editas Medicine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Editas Medicine income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Editas Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Net Income	+ 1.0	Ebit
Total Operating Expenses	+ 1.0	Research Development

Operating Income	- 0.96	Selling General Administrative
Ebitda	- 0.95	Selling General Administrative
Ebit	- 0.95	Selling General Administrative
Total Operating Expenses	- 0.94	Operating Income
Operating Income	- 0.94	Other Operating Expenses
Net Income	- 0.94	Selling General Administrative